Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function
{{output}}
Objective: In November 2022, teplizumab-mzwv became the first drug approved to delay the onset of stage 3 type 1 diabetes in adults and children age ≥8 years with stage 2 type 1 diabetes on the basis of data from the pivotal stu... ...
